Junshi Biosciences News and Activities
Presence
Junshi Biosciences develops and sells biopharmaceutical medicines. Its main products include cancer, autoimmune, and infectious disease treatments for hospitals, healthcare providers, and patients.
Junshi Biosciences products and services overview:
- Cancer treatments
- Autoimmune therapies
- Infectious disease drugs
- Biologic medicines
- Drug discovery services
Revenue: ~$270 million
Employees: 2,500
Headquarters: Shanghai, China
Junshi Biosciences is one of the...
Junshi Biosciences is a company listed under the stock ticker 688180 (HK).
Executives
View the org chart displaying its 27 main executives
Most searched biographies at Junshi Biosciences
- Jianjun Zou, Managing Director and Chief Executive Officer
- Tang Yi, Non-Executive Director
- Lu Kun, Independent Non-executive Directors
Create your alert
to follow the executive moves at Junshi Biosciences.
Biotechnology
Junshi Biosciences has 2,425 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).
Popular M&A news in Biotechnology
- Chemomab and Scipher Medicine have announced they will merge (posted on July 13 2026)..
- Chemomab and Scipher Medicine have announced they will merge (posted on July 13 2026)..
- Apnimed has filed its IPO. Its stock ticker will be APMD. (posted on July 13 2026).
Popular contacts in Biotechnology
News
Press releases by Junshi Biosciences
Social media about Junshi Biosciences
- Junshi Biosciences on Wikipedia, Google News & Yahoo Finance
- Junshi Biosciences on LinkedIn, X (Twitter) & YouTube
